BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 20686373)

  • 1. The role of diaphragmatic surgery during interval debulking after neoadjuvant chemotherapy: an analysis of 74 patients with advanced epithelial ovarian cancer.
    Tsolakidis D; Amant F; Van Gorp T; Leunen K; Neven P; Vergote I
    Int J Gynecol Cancer; 2010 May; 20(4):542-51. PubMed ID: 20686373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB-IV epithelial ovarian cancer.
    Tsolakidis D; Amant F; Van Gorp T; Leunen K; Neven P; Vergote I
    Gynecol Oncol; 2010 Mar; 116(3):489-96. PubMed ID: 19954825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
    Zhao D; Wu LY; Wang XB; Li XG
    Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.
    Corrado G; Mancini E; Cutillo G; Baiocco E; Vici P; Sergi D; Patrizi L; Saltari M; Baffa A; Vizza E
    Int J Gynecol Cancer; 2015 Sep; 25(7):1253-7. PubMed ID: 26111273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy.
    Fagotti A; Gueli Alletti S; Corrado G; Cola E; Vizza E; Vieira M; Andrade CE; Tsunoda A; Favero G; Zapardiel I; Pasciuto T; Scambia G
    Int J Gynecol Cancer; 2019 Jan; 29(1):5-9. PubMed ID: 30640676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
    Ren Y; Shi T; Jiang R; Yin S; Wang P; Zang R
    Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
    Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.
    Van de Putte G; Oben J; Prenen L; Schobbens JC; Vlasselaer J; Van Holsbeke C; Debrock G; Van Eycken P; de Jonge E
    Int J Gynecol Cancer; 2015 Jul; 25(6):993-9. PubMed ID: 25914962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yildirim Y; Ertas IE; Dogan A; Gultekin OE; Gultekin E
    J Surg Oncol; 2012 Feb; 105(2):200-5. PubMed ID: 21815151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of diaphragmatic surgery at primary or interval debulking in advanced ovarian carcinoma: an analysis of 163 patients.
    Tsolakidis D; Amant F; Leunen K; Cadron I; Neven P; Vergote I
    Eur J Cancer; 2011 Jan; 47(2):191-8. PubMed ID: 20880697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
    Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.
    Saha A; Varughese M; Gallagher CJ; Orphanos G; Wilson P; Oram D; Jeyarajah A; Reynolds K; Shepherd J; McCormack M; Olaitan A; McDonald N; Mould T; McNeish I; Ledermann JA
    Int J Gynecol Cancer; 2012 May; 22(4):566-72. PubMed ID: 22426404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
    Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
    Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
    Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
    Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymph node metastasis in grossly apparent stages I and II epithelial ovarian cancer.
    Nomura H; Tsuda H; Susumu N; Fujii T; Banno K; Kataoka F; Tominaga E; Suzuki A; Chiyoda T; Aoki D
    Int J Gynecol Cancer; 2010 Apr; 20(3):341-5. PubMed ID: 20375794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of Diaphragmatic Surgery During Interval Debulking Surgery.
    Pelissier A; Franke O; Darai E; Houvenaeghel G; Chereau E; Rouzier R
    Anticancer Res; 2018 Jan; 38(1):411-416. PubMed ID: 29277802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
    Kuhn W; Rutke S; Späthe K; Schmalfeldt B; Florack G; von Hundelshausen B; Pachyn D; Ulm K; Graeff H
    Cancer; 2001 Nov; 92(10):2585-91. PubMed ID: 11745193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of 'patterns of care' of ovarian cancer patients in a specialized cancer institute in Kolkata, eastern India.
    Basu P; De P; Mandal S; Ray K; Biswas J
    Indian J Cancer; 2009; 46(1):28-33. PubMed ID: 19282563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.